HRT Financial’s Altamira Therapeutics Ltd CYTO Stock Holding History

HRT Financial’s Portfolio CYTO Stock Details CYTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-59	Closed	-$6K	–	3453
2022 Q3	$6K	Buy	+59	New	+$9.79K	﹤0.01%	2582
2022 Q2	–	Sell	-44	Closed	-$19K	–	3971
2022 Q1	$19K	Buy	+44	New	+$21.2K	﹤0.01%	2842
2020 Q4	–	Sell	-60	Closed	-$19K	–	2641
2020 Q3	$19K	Buy	+60	New	+$22.6K	﹤0.01%	1781

Other funds holding CYTO

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SCA

Stonebridge Capital Advisors St Paul, Minnesota $1.43B AUM 21.98% 1-Year Est. Return

HRT Financial's CYTO Position: Q4 2022 in Review

HRT Financial sold out of Altamira Therapeutics Ltd (CYTO) in Q4 2022, closing a stake of 59 shares — an estimated $6K sold.

HRT Financial first reported a position in CYTO in Q3 2020 and held it in 3 quarters. The position peaked at $19K in Q1 2022. 6 funds tracked by Wall St. Rank hold CYTO as of Q4 2022.

HRT Financial reported no remaining Altamira Therapeutics Ltd position as of Q4 2022 after selling out during the quarter.
HRT Financial sold 59 Altamira Therapeutics Ltd shares in Q4 2022, an estimated $6K.
HRT Financial first reported a position in Altamira Therapeutics Ltd in Q3 2020 and held it in 3 quarters.
HRT Financial's Altamira Therapeutics Ltd position peaked at $19K in Q1 2022.
6 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2022.

Based on HRT Financial's 13F filing for Q4 2022, filed 10 Feb 2023.